Dynavax Technologies Corp (NASDAQ:DVAX)

CAPS Rating: 3 out of 5

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.

Recs

0
Player Avatar KimLanners (< 20) Submitted: 7/20/2011 12:04:39 PM : Outperform Start Price: $2.52 DVAX Score: +44.84

biot

Featured Broker Partners


Advertisement